<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huenges Wajer IMC</submitter><funding>Netherlands Heart Foundation</funding><pagination>1486-1489</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6282849</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(12)</volume><pubmed_abstract>&lt;h4>Background and purpose&lt;/h4>In randomized trials magnesium supplementation did not improve clinical outcome after aneurysmal subarachnoid haemorrhage (aSAH) on handicap scales. After aSAH, many patients have cognitive problems that may not translate into handicap. The effect of magnesium on cognitive outcome after aSAH was studied.&lt;h4>Methods&lt;/h4>In total, 209 patients who had been included in the Magnesium for Aneurysmal Subarachnoid Haemorrhage (MASH-2) trial in the University Medical Centre of Utrecht were studied. Patients had been randomized to 64 mmol magnesium sulfate daily or placebo during hospitalization. Three months after aSAH patients underwent a neuropsychological examination (NPE) consisting of six neuropsychological tests or a brief cognitive assessment. Poisson and line</pubmed_abstract><journal>European journal of neurology</journal><pubmed_title>Effect of magnesium on cognition after aneurysmal subarachnoid haemorrhage in a randomized trial.</pubmed_title><pmcid>PMC6282849</pmcid><funding_grant_id>2005BO16</funding_grant_id><pubmed_authors>Rinkel GJE</pubmed_authors><pubmed_authors>Huenges Wajer IMC</pubmed_authors><pubmed_authors>van Zandvoort MJE</pubmed_authors><pubmed_authors>Dorhout Mees SM</pubmed_authors><pubmed_authors>van den Bergh WM</pubmed_authors><pubmed_authors>Algra A</pubmed_authors><pubmed_authors>Visser-Meily JMA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of magnesium on cognition after aneurysmal subarachnoid haemorrhage in a randomized trial.</name><description>&lt;h4>Background and purpose&lt;/h4>In randomized trials magnesium supplementation did not improve clinical outcome after aneurysmal subarachnoid haemorrhage (aSAH) on handicap scales. After aSAH, many patients have cognitive problems that may not translate into handicap. The effect of magnesium on cognitive outcome after aSAH was studied.&lt;h4>Methods&lt;/h4>In total, 209 patients who had been included in the Magnesium for Aneurysmal Subarachnoid Haemorrhage (MASH-2) trial in the University Medical Centre of Utrecht were studied. Patients had been randomized to 64 mmol magnesium sulfate daily or placebo during hospitalization. Three months after aSAH patients underwent a neuropsychological examination (NPE) consisting of six neuropsychological tests or a brief cognitive assessment. Poisson and line</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Dec</publication><modification>2026-07-16T08:00:15.397Z</modification><creation>2019-03-27T00:11:16Z</creation></dates><accession>S-EPMC6282849</accession><cross_references><pubmed>30048027</pubmed><doi>10.1111/ene.13764</doi></cross_references></HashMap>